Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2014, Article ID 473482, 5 pages
http://dx.doi.org/10.1155/2014/473482
Clinical Study

Effect of Gender on Coagulation Functions: A Study in Metastatic Colorectal Cancer Patients Treated with Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin

Bülent Ecevit University School of Medicine, Department of Internal Medicine, Division of Medical Oncology, 67100 Zonguldak, Turkey

Received 12 June 2014; Revised 22 July 2014; Accepted 6 August 2014; Published 21 August 2014

Academic Editor: Aldo Roccaro

Copyright © 2014 Cemil Bilir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Ferroni, V. Formica, M. Roselli, and F. Guadagni, “Thromboembolic events in patients treated with anti-angiogenic drugs,” Current Vascular Pharmacology, vol. 8, no. 1, pp. 102–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu, “Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis,” JAMA—Journal of the American Medical Association, vol. 300, no. 19, pp. 2277–2285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. H. I. Hurwitz, L. B. Saltz, E. van Cutsem et al., “Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies,” Journal of Clinical Oncology, vol. 29, no. 13, pp. 1757–1764, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Ustuner, O. M. Akay, M. Keskin, E. Kuş, C. Bal, and Z. Gulbas, “Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography,” Medical Oncology, vol. 29, no. 5, pp. 3125–3128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Pectasides, D. Tsavdaridis, C. Aggouridaki et al., “Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients,” Anticancer Research, vol. 19, no. 4, pp. 3521–3526, 1999. View at Google Scholar · View at Scopus
  7. C. C. Kirwan, G. McDowell, C. N. McCollum, S. Kumar, and G. J. Byrne, “Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer,” British Journal of Cancer, vol. 99, no. 7, pp. 1000–1006, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. E. C. Gabazza, O. Taguchi, T. Yamakami et al., “Coagulation-fibrinolysis system and markers of collagen metabolism in lung cancer,” Cancer, vol. 70, pp. 2631–2636, 1992. View at Google Scholar
  9. J. L. Spivak, “The anaemia of cancer: death by a thousand cuts,” Nature Reviews Cancer, vol. 5, no. 7, pp. 543–555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Komurcuoglu, S. Ulusoy, M. Gayaf, A. Guler, and E. Ozden, “Prognostic value of plasma D-dimer levels in lung carcinoma,” Tumori, vol. 97, no. 6, pp. 743–748, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Altiay, A. Ciftci, M. Demir et al., “High plasma d-dimer level is associated with decreased survival in patients with lung cancer,” Clinical Oncology, vol. 19, no. 7, pp. 494–498, 2007. View at Publisher · View at Google Scholar · View at Scopus